News
Company News: Richter launched Terrosa®, its biosimilar teriparatide across Europe
Gedeon Richter Plc. (“Richter”) today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly’s Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. Read more…
Company News: Curetis Retains H.C. Wainwright & Co. as Strategic Advisor
— Investment bank supports Curetis in assessment of all strategic and tactical financing options
— Publication of H1-2019 financials postponed to September 18, 2019
— Key financials show EUR 7.8 million cash as of June 30, 2019 and significantly reduced cash burn in H1-2019
Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank, H.C. Wainwright & Co., LLC, as strategic advisor in an effort to assess all available strategic and tactical options going forward to potentially secure appropriate funding and cash for continued operations for at least the next twelve months. Read more…
Company News: Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing
— Initial focus on non-diagnostic testing with Next Generation Sequencing (NGS) for infection control, outbreak management and research
— First commercial orders received and processed
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH has opened a specialized service laboratory offering next-generation molecular antimicrobial resistance (AMR) testing services with an initial focus on infection control, AMR epidemiology and surveillance, clinical research and pharmaceutical anti-infectives R&D. Read more…
Company News: Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes
– Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible bonds has been reached
– Curetis elects to settle the excess entitlement under the first tranche in shares
Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation. Read more…